Related references
Note: Only part of the references are listed.Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials
Steven R. Feldman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2021)
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
J. Bagel et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2•5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial
A. B. Gottlieb et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis
A. Egeberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Desiree van der Heijde et al.
RHEUMATOLOGY (2020)
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Z. Z. N. Yiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis
Marco Galluzzo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response
N. Rompoti et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study
Ricardo Ruiz-Villaverde et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era
Marco Galluzzo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study
Philip J. Mease et al.
ACR OPEN RHEUMATOLOGY (2020)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Psoriasis Pathogenesis and Treatment
Adriana Rendon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis A systematic review and meta-analysis
Li Zhang et al.
MEDICINE (2019)
The IL-17 Family of Cytokines in Health and Disease
Mandy J. McGeachy et al.
IMMUNITY (2019)
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study
Eleni Kampylafka et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2019)
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study
A. Costanzo et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluis Puig et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study)
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study
Laura C. Coates et al.
ARTHRITIS CARE & RESEARCH (2018)
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Philip J. Mease et al.
RMD OPEN (2018)
Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
Eleni Kampylafka et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel et al.
DERMATOLOGY AND THERAPY (2018)
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Peter Nash et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
L. C. Coates et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
Neil J. Korman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
A systematic review of worldwide epidemiology of psoriasis
I. M. Michalek et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis
Steven R. Feldman et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2017)
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Psoriasis and comorbid diseases Implications for management
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study
A. Blauvelt et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
Iain B. McInnes et al.
RHEUMATOLOGY (2017)
Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2017)
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial
M. Sticherling et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Role of the HLA-C☆06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients
M. Talamonti et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis
Ju Yeon Ryoo et al.
ANNALS OF PHARMACOTHERAPY (2016)
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
EXPERT OPINION ON DRUG SAFETY (2016)
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
Shinichi Imafuku et al.
JOURNAL OF DERMATOLOGY (2016)
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
D. Thaci et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Secukinumab shows efficacy in subjects regardless of previous exposure to biologic therapy: A pooled subanalysis from four phase 3 clinical trials in psoriasis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology and Pathogenesis of Psoriasis
Wolf-Henning Boehncke
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
Richard G. B. Langley et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis
H. -Y. Chiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Psoriasis
Paola Di Meglio et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis
Senem Buyukkara Yilmaz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Measuring Disease Activity in Psoriatic Arthritis
Priscilla C. H. Wong et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2012)
Serum cytokines and growth factor levels in Japanese patients with psoriasis
H. Takahashi et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Psoriasis Comorbidities
Lyn Guenther et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2009)
Structure and signalling in the IL-17 receptor family
Sarah L. Gaffen
NATURE REVIEWS IMMUNOLOGY (2009)
Expression of Th17 cytokines in skin lesions of patients with psoriasis
Li Jiawen et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2007)
Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity
O Arican et al.
MEDIATORS OF INFLAMMATION (2005)
Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis
P Rich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients
D Thaci et al.
DERMATOLOGY (2001)
Share Paper
